Fresenius Medical Care AG & Co. KGaA Sponsored ADR Stock News

Strong organic revenue growth1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million contributed to earnings Operating income2 grew 11% at constant currency resulting in margin expansion Reported operating income grew by 35% and reported net income3 by 113% Net leverage ratio furthe...

World's largest dialysis specialist Fresenius Medical Care reported first-quarter results above analysts' expectations on Tuesday, as revenue grew organically in all its segments, it said.

In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders Fresenius Medical Care delivered 18% operating income growth on an outlook base in 2024 Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprint BAD HOMBURG, Germany , M...

Dialysis firm Fresenius Medical Care shares fell 7.8% after German healthcare group Fresenius SE sold part of its stake in the company.

Organic revenue growth1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 million With 18% operating income2 growth top end of the 2024 outlook range reached Reported operating inco...

Fresenius Medical Care , the world's largest dialysis specialist, reported fourth quarter results slightly above market expectations on Tuesday, citing positive development both in its care delivery and care enablement segments.

Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NY...

Fresenius Medical Care is a leader in global kidney care, showing significant growth and an 18.5% increase since my last article. The company is attractively valued, trading at less than 18.5x P/E, with a fair value estimate of at least $34/share. Risks include political factors in the US healthcare system and technological advancements, but the company's diversification and home-care model are...